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Off-Label Drug Uses

Guidelines
American Urological Association
American Urological Association (AUA) guidelines on the diagnosis and management of interstitial cystitis/bladder pain syndrome present a tiered approach to treatment based on expert opinion and an evidencebased review of published data. First-line treatment, which includes education regarding normal bladder function and self-care practices/behavioral modifi cations that can improve symptoms, is recommended for all patients. Second-line therapy includes multimodal pain management, physical therapy, and oral (amitriptyline, cimetidine, hydroxyzine, or pentosan hydrochloride) or intravesical (dimethylsulfoxide, heparin, or lidocaine) agents that have demonstrated limited effi cacy in a subset of patients and an uncertain risk-benefi t ratio. Evidence for amitriptyline includes a single randomized controlled trial and 2 observational studies demonstrating benefi t superior to placebo but also the potential for adverse effects that compromise quality of life (eg, sedation, drowsiness, nausea). Based on its potential for
BACKGROUND
Interstitial cystitis/bladder pain syndrome is a chronic condition characterized by an unpleasant suprapubic sensation of the urinary bladder (pain, pressure, discomfort) accompanied by lower urinary tract symptoms of more than 6 weeks' duration that are not due to infection or other causes. 1 Interstitial cystitis/bladder pain syndrome is more prevalent in women but can affect men as well. Etiology is poorly defined and therefore hampers classification and treatment; current treatments are not uniformly effective. [1] [2] [3] Mast cell degranulation within the bladder wall, possibly related to histamine release, has been proposed as a contributing factor in the infl ammatory process. 3 Amitriptyline acts via the blockade of acetylcholine receptors, inhibition of reuptake of released serotonin and norepinephrine, and blockade of histamine H 1 receptors. 4 
PATIENT POPULATION
Adults with signs and symptoms of interstitial cystitis/bladder pain syndrome.
DOSAGE AND DURATION
Ten to 25 mg daily titrated weekly over several weeks, to a target dose of 75 to 100 mg as tolerated for up to 23 months.
RESULTS
Amitriptyline in the management of interstitial cystitis/bladder pain syndrome has been studied in a limited number of controlled and noncontrolled trials (enrolling more than 200 patients) demon-Volume 49, October 2014 benefi t in a small subset of patients, amitriptyline was assigned an option strength recommendation. Thirdline treatment includes bladder distention or Hunner lesion treatment. Sacral/pudendal nerve stimulation is recommended as fourth-line management. Oral cyclosporine or botulinum toxin injections administered by an experienced clinician are recommended as fi fth-line management. Surgical intervention (eg, substitution cystoplasty, urinary diversion) is suggested as sixth-line therapy. 1 
Controlled trial
In a double-blind, placebo-controlled, multicenter trial published after the AUA guidelines were issued, 271 therapy-naive adult patients with interstitial cystitis/bladder pain syndrome were randomized to receive placebo or amitriptyline for 12 weeks. Amitriptyline was increased at weekly intervals from 10 mg to 25 mg, then to 50 mg daily. At the end of 3 weeks, patients were evaluated and, based on tolerability, the dose was increased to a maximum of 75 mg daily; this dose was maintained as tolerated until the 12-week assessment. All patients participated in an Educational and Behavioral Modifi cation Program (EBMP). The primary outcome was the proportion of responders between treatment arms based on a 7-item global response assessment (GRA) scale that ranks symptoms from markedly worse to markedly improved. Responders were defi ned as patients indicating moderately or markedly improved symptoms; noncompleters were considered treatment failures. Secondary outcomes included urinary pain, urgency, and frequency measured via an 11-point Likert scale, a 24-hour voiding diary, and a variety of symptom scales. A total of 235 subjects completed the 12-week trial, with 23 (17%) and 17 (13%) withdrawing from the amitriptyline and placebo groups, respectively. Mean ages were 38 years and 39.9 years, respectively. Response rates at 12 weeks were not signifi cantly different between the amitriptyline and placebo groups (55% vs 45%, respectively; P = .12); however, in the subset of patients achieving a dose of at least 50 mg daily, a significantly higher response rate was observed in the amitriptyline group (66% vs 47% with placebo; P = .01). It should be noted that of the patients who achieved a dose of at least 50 mg daily by 6 weeks, approximately 20% in the amitriptyline group and 15% in the placebo group decreased their dose in the second 6-week period. In the subset of patients who achieved and maintained the higher dose for the remainder of the study, response rates were higher for both groups and were significantly higher in the amitriptyline group compared with placebo (77% vs 53%; P < .001). In addition, overall GRA response rates were higher in patients who adhered to the EBMP compared with nonadherers.
5
SAFETY
This is a limited safety profi le. Refer to package labeling for complete prescribing information (eg, Warnings/Precautions, Adverse Reactions, Drug Interactions).
In reviewed data, adverse events were very common (affecting up to 80% of patients) and included sedation, drowsiness, dizziness, and nausea. 1, [5] [6] [7] 
THERAPY CONSIDERATIONS
Amitriptyline in the management of interstitial cystitis/bladder pain syndrome has been studied in a limited number of controlled and noncontrolled trials demonstrating effi cacy rates of 50% to 66%, with higher effi cacy rates (up to 77%) at sustained higher doses (at least 50 mg daily). Tolerance at higher doses is unlikely. AUA guidelines recommend oral amitriptyline as a second-line treatment option that may provide benefi t in a subset of patients; however, adverse events potentially affecting quality of life (eg, drowsiness, nausea) are common.
